Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more here.
A topical therapy to treat shingles and shingles-induced pain
Our current priority is developing our undecylenic acid-based formulation, Solexan™, for shingles and shingles pain.
Wintermute is now recruiting shingles patients for a Phase Ib Clinical Trial to test Solexan™, a potential new therapy for shingles and shingles pain.
Who Can Participate?
Adults aged 18 and over.
Visible shingles rash presented within the last 5 days.
Think You Might Have Shingles?
Early diagnosis is crucial for effective treatment.
If you're experiencing symptoms but aren't sure if it's shingles, see your doctor as soon as possible, or contact our trial sites if you are interested in participating in our study.
Our team can help assess your eligibility and schedule a prompt evaluation.
Why Participate?
Access to a potentially effective new treatment.
Contribute to important medical research.
Receive study-related care at no cost.
Possible compensation for time and travel.
Trial Locations
Patients interested in participating in the study can contact our Melbourne or Sydney trial sites.
Maxwell Medical Group, Melbourne
Central West Shopping Centre
T22, 65-67 Ashley Street
Braybrook VIC 3019
Phone: (03) 7036 2450
Ground Floor
281 Elizabeth Street
Sydney NSW 2000
(inside Regency Hyde Park building)
Phone: (02) 8262 1000
Learn more about the trial here.
Shingles (Herpes Zoster) is caused by the Varicella Zoster Virus. Primary infection with the virus causes Chicken Pox, usually in children. After symptoms subside, the virus lies dormant in nerves, sometimes for decades. Shingles occurs when the virus reactivates, typically brought on by stress or a weakened immune system. Shingles is most common in the elderly population, and one in three people will develop shingles in their lifetime.
Shingles is a painful disease, with a painful rash presenting on the torso, and sometimes on the face and limbs. Symptoms typically subside within seven to ten days, but in some patients, shingles can cause other medical complications. One in five people over 50 will develop post-herpetic neuralgia, pain that remains after symptoms have resolved. In some cases, pain can remain for months or years; 15% of patients experience pain for years, causing a significant burden to their quality of life.
The current frontline treatment for shingles is oral antivirals. Unfortunately, these drugs are only effective if given within three days of symptom onset, meaning many patients are left with only painkillers to treat the disease.
Learn more about shingles here.
Solexan™ is an innovative topical treatment being investigated for shingles and shingles-related pain. As a topical foam, Solexan™ can be easily applied to shingles lesions, making it simple for patients to self-administer.
Solexan™ has already been FDA-registered as a topical antifungal, meaning its safety profile is already well established.
In collaboration with Professor Jennifer Moffat at Upstate Medical University NY, we have found encouraging evidence that Solexan™ can penetrate the skin to directly target the shingles virus.
We believe this could be the key to reducing shingles-induced pain and speeding up healing.